Feb 14 (Reuters) - Delcath Systems DCTH.O:
DELCATH SYSTEMS ANNOUNCES UPDATE TO NATIONAL COMPREHENSIVE CANCER NETWORK CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT OF METASTATIC UVEAL MELANOMA
DELCATH SYSTEMS: UPDATED NCCN GUIDELINES INCLUDE HEPZATO KIT AS CATEGORY 2A TREATMENT FOR PATIENTS WITH HEPATIC-DOMINANT UVEAL MELANOMA
Source text: ID:nBw4Rt5FZa
Further company coverage: DCTH.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.